Heghine Khachatryan: The Future of Anticoagulation Beyond DOACs
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from JTH on LinkedIn, about a recent article by Holly Dobbing et al, adding:
”Beyond DOACs: The Future of Anticoagulation
The recently highlighted article in the Journal of Thrombosis and Haemostasis explores novel and experimental anticoagulant strategies beyond current DOACs — a rapidly evolving field with profound clinical implications.
While direct oral anticoagulants (DOACs) have transformed thrombosis management, significant unmet needs remain:
- Patients with high bleeding risk
- Mechanical heart valves
- Advanced renal impairment
- Antiphospholipid syndrome
- Recurrent thrombosis despite standard therapy
Emerging therapeutic targets such as Factor XI and XIa inhibitors, RNA-based approaches, and next-generation selective pathway modulation aim to provide:
- Effective thrombosis prevention
- Reduced bleeding liability
- More precise coagulation control
For clinicians working in thrombosis and hemostasis, this represents a paradigm shift — moving from broad anticoagulation toward mechanism-refined, safer antithrombotic strategies.
As we continue strengthening thrombosis care systems in Armenia and globally, staying aligned with these innovations is essential for advancing patient safety and equity in treatment access.
Highly recommended reading for hematologists, cardiologists, and clinical researchers.”
Quoting Journal of Thrombosis and Haemostasis (JTH)‘s post:
”Novel and Experimental Anticoagulant Strategies Beyond Current DOACs
Emerging anticoagulation strategies explore contact pathway inhibition, fibrin targeting, and natural anticoagulant pathway enhancement to address DOAC limitations, promising safer thrombosis treatment with reduced bleeding risks for cardiovascular disease management.”
Title: Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants
Authors: Holly Dobbing, Katherine L. Webb, Robert Ariëns
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 14:16Erin VanDyke: Next Generation Is Leading the Way in Pediatric VTE Care
-
Apr 15, 2026, 14:13Shahzeb Hassan: Pulmonary Embolism – What to Do When Every Minute Matters
-
Apr 15, 2026, 14:06Hossam El Benawi: Intensive Blood Pressure Reduction May Worsen Outcomes After Thrombectomy
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy